Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.

Therapeutic drug monitoring - 1 Dec 2012

Lemaitre Florian, Bezian Elodie, Goldwirt Lauriane, Fernandez Christine, Farinotti Robert, Varnous Shaida, Urien Saik, Antignac Marie

Abstract excerpt

BACKGROUND: The aim of this study was, using routine drug monitoring data, to identify patient characteristics that may influence everolimus (EVE) pharmacokinetic parameters and to develop a population pharmacokinetic model to predict EVE whole blood concentrations in cardiac recipients. METHODS: Fifty-nine patients were enrolled in the prospective study. Patient's characteristics were recorded including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Everolimus

Share to Graft Rejection

Share to Heart Transplantation

Share to Sirolimus

Source

Identifiers

PMID: 23131698
DOI: 10.1097/FTD.0b013e318273c899

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.PMID 23131698Read ↗

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.Semantic proximity Read ↗

A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.Semantic proximity Read ↗

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.Semantic proximity Read ↗

Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.Semantic proximity Read ↗

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients.Semantic proximity Read ↗

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients.Semantic proximity Read ↗

The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.Semantic proximity Read ↗

Development and validation of a population pharmacokinetic model to guide perioperative tacrolimus dosing after lung transplantationSemantic proximity Read ↗

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.Semantic proximity Read ↗

Pharmacokinetics of immunosuppressants: a perspective on ethnic differencesSemantic proximity Read ↗

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.